The U.S. Food and Drug Administration has approved odevixibat (Bylvay; Albireo Pharma, Inc) for the treatment of pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC), according to a press release. Odevixibat...

The U.S. Food and Drug Administration has approved anifrolumab-fnia (Saphnelo; AstraZeneca), a first-in-class type I interferon receptor antagonist for adults with moderate to severe systemic lupus erythematosus (SLE), according to a press release....

Although progress in survival trends for brain cancer, lung cancer, acute myeloid leukemia, and colon and rectum cancers in adolescents has been made over the last 40 years, new research shows that minimal...

Mycophenolate mofetil (MMF) appears safe and effective as a second-line immunosuppressive agent in patients with thyroid eye disease (TED), according to a study. In this retrospective cohort study, 20 patients with active moderate-severe to sight-threatening...

Preventing early hospital readmission in patients with interstitial lung disease (ILD) may impact clinical course in these patients, according to a study that found that early readmission increased short-term and long-term mortality. In...